FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Amado Rafael						2. Issuer Name and Ticker or Trading Symbol Allogene Therapeutics, Inc. [ALLO]									tionship of Reportir all applicable) Director Officer (give title		ng Per	rson(s) to Is 10% O Other (wner
(Last) (First) (Middle) 210 EAST GRAND AVE						3. Date of Earliest Transaction (Month/Day/Year) 10/01/2021									below)		below)		Specify
	orreet) OUTH SAN RANCISCO CA 94080			4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								i. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(Sta	ate) (Z	Zip)																
		Table	I - N	Non-Deriva	tive	Secui	rities	Ac	quir	ed, Di	sposed c	f, or	Benefic	ially	Own	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea				ear) E	2A. Deemed Execution D if any (Month/Day		, [3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			nd 5) Secur Benet		icially d Following	Form (D) o	ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							ď		v .	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)		(iiisti	,	(111341. 4)	
Common Stock 10/01/2021					1				S ⁽¹⁾		11,507	D	\$24.34	4.3491 ⁽²⁾		323,928		D	
		Tal	ble I	II - Derivati (e.g., pu						,	posed of, converti			•	Owne	d			
Derivative Conversion Date Execuserity or Exercise (Month/Day/Year) if any			Deemed cution Date, iy nth/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)				le and unt of unt of urities erlying vative urity (Instr. d 4)	Der Sec (Ins	rice of vative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	

Explanation of Responses:

- 1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$24.17 to \$24.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Remarks:

Veer Bhavnagri as attorney-infact for Rafael Amado

10/04/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.